Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice?

被引：10
|
作者：
Prytula, Agnieszka [1 ]
Cransberg, Karlien [2 ]
Raes, Ann [1 ,3 ]
机构：
[1] Ghent Univ Hosp, Paediat Nephrol & Rheumatol Dept, C Heymanslaan 10, B-9000 Ghent, Belgium
[2] Sophia Childrens Univ Hosp, Erasmus MC, Paediat Nephrol Dept, Rotterdam, Netherlands
[3] Safepedrug Unit, Ghent, Belgium
来源：
PEDIATRIC NEPHROLOGY | 2019年 / 34卷 / 07期
关键词：
Calcineurin inhibitors; CYP3A; CYP3A4; CYP3A5; Vitamin D; Mineral and bone disorder; Renal transplantation; SINGLE NUCLEOTIDE POLYMORPHISMS; CYCLOSPORINE-A; IN-VITRO; BONE LOSS; 1-ALPHA; 25-DIHYDROXYVITAMIN D-3; CALCINEURIN INHIBITORS; GENETIC POLYMORPHISMS; MINERAL METABOLISM; DOSE REQUIREMENTS; LIVER;
D O I：
10.1007/s00467-018-4030-3
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
CYP3A enzymes are involved in the metabolism of calcineurin inhibitor tacrolimus as well as vitamin D. In this review, we summarize the clinical aspects of CYP3A-mediated metabolism of tacrolimus and vitamin D with emphasis on the influence of single-nucleotide polymorphisms on tacrolimus disposition. We describe the utility of 4 hydroxycholesterol as a marker of CYP3A activity. Then, we discuss the possible interaction between calcineurin inhibitors and vitamin D in solid organ transplant recipients. Also, we review other mechanisms which may contribute to side effects of calcineurin inhibitors on bone. Lastly, suggestions for future research and clinical perspectives are discussed.
引用
收藏
页码：1201 / 1210
页数：10
相关论文
共 45 条
  • [1] Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice?
    Agnieszka Prytuła
    Karlien Cransberg
    Ann Raes
    Pediatric Nephrology, 2019, 34 : 1201 - 1210
  • [2] Paxlovid (Nirmatrelvir/Ritonavir)-Induced Tacrolimus Toxicity in Organ Transplant Recipients - A Review on Drug Interactions Involving CYP3A Enzymes
    Maideen, Naina Mohamed Pakkir
    Al Rashid, Sulthan
    CURRENT DRUG SAFETY, 2024,
  • [3] Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa
    Ekhart, Corine
    Doodeman, Valerie D.
    Rodenhuis, Sjoerd
    Smits, Paul H. M.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (01) : 50 - 60
  • [4] The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
    Ingrid Lunde
    Sara Bremer
    Karsten Midtvedt
    Beata Mohebi
    Miriam Dahl
    Stein Bergan
    Anders Åsberg
    Hege Christensen
    European Journal of Clinical Pharmacology, 2014, 70 : 685 - 693
  • [5] Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients
    Chen, Dina
    Lu, Huijie
    Sui, Weiguo
    Li, Liqing
    Xu, Jian
    Yang, Tengfei
    Yang, Siyao
    Zheng, Ping
    Chen, Yan
    Chen, Jiejing
    Xue, Wen
    Li, Qingping
    Zheng, Que
    Ye, Demei
    Sadee, Wolfgang
    Wang, Danxin
    Qian, Wanying
    Lai, Liusheng
    Li, Chuanjiang
    Li, Liang
    PHARMACOGENOMICS JOURNAL, 2021, 21 (03): : 376 - 389
  • [6] Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients
    Dina Chen
    Huijie Lu
    Weiguo Sui
    Liqing Li
    Jian Xu
    Tengfei Yang
    Siyao Yang
    Ping Zheng
    Yan Chen
    Jiejing Chen
    Wen Xue
    Qingping Li
    Que Zheng
    Demei Ye
    Wolfgang Sadee
    Danxin Wang
    Wanying Qian
    Liusheng Lai
    Chuanjiang Li
    Liang Li
    The Pharmacogenomics Journal, 2021, 21 : 376 - 389
  • [7] The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
    Lunde, Ingrid
    Bremer, Sara
    Midtvedt, Karsten
    Mohebi, Beata
    Dahl, Miriam
    Bergan, Stein
    Asberg, Anders
    Christensen, Hege
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (06) : 685 - 693
  • [8] Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes - detailed studies on CYP3A inhibitors
    Kahma, Helina
    Paludetto, Marie-Noelle
    Neuvonen, Mikko
    Kurkela, Mika
    Filppula, Anne M.
    Niemi, Mikko
    Backman, Janne T.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 198
  • [9] Interplay between vitamin D and the drug metabolizing enzyme CYP3A4
    Wang, Zhican
    Schuetz, Erin G.
    Xu, Yang
    Thummel, Kenneth E.
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2013, 136 : 54 - 58
  • [10] Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients
    Katsakiori, Paraskevi F.
    Papapetrou, Eirini P.
    Goumenos, Dimitrios S.
    Nikiforidis, George C.
    Flordellis, Christodoulos S.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 : 265 - 269
12345